Vect-Horus

Meet Vect-Horus at BIO Japan, October 8-10, 202

Emmanuelle BETTENDORF — 2025-09-19T14:17:17Z

We are excited to be attending BioJapan, taking place October 8-10.
Our Senior Business Developer Faustine Ramel will be in Yokohama for the event – please let us know if you would like to schedule a meeting.
https://jcd-expo.jp/en/

- News / Agenda

Meet Vect-Horus at OTS, Montreal, October 6-9, 2024

Emmanuelle BETTENDORF — 2024-10-02T13:48:38Z

Guillaume Jacquot and Emmanuelle Bettendorf will be representing Vect-Horus at the The Oligonucleotide Therapeutics Society (OTS) Annual Meeting, taking place in Montreal, Canada from October 6-9.

This is the leading international meeting of renowned oligonucleotide scientists, bringing academia, research and business together, and we are excited to swap notes with other leading players in the field.

👉 Click here for more on the meeting www.2024oligomeeting.com

Meet Vect-Horus at San Diego, California, June 3-6, 2024

Emmanuelle BETTENDORF — 2024-05-21T13:56:40Z

Next month, Emmanuelle Bettendorf will be attending the BIO International Convention, a major biotech industry conference taking place in San Diego, CA from June 3-6, 2024, and will be available to meet with you on partnership opportunities.
Looking forward to seeing you there!

- News / Agenda

Vect-Horus Nominated for the 2024 Biotech Trophy Award, Organized by France Biotech

Emmanuelle BETTENDORF — 2024-03-21T15:09:36Z

Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has been nominated for the 2024 Biotech Trophy award, organized by the France Biotech industry association.

The award recognizes a biotech company which has distinguished itself in the past two years by particularly remarkable advances in R&D, operational development, partnerships or financing.

This nomination reflects the progress made by Vect-Horus in the domain of drug delivery of therapeutic drugs to the central nervous system (CNS) and the recent signing of two major licensing agreements with Novo Nordisk and Ionis Pharmaceuticals. As a result, Vect-Horus has become a key global player in this field.

“We are proud to be recognized by France Biotech for our technology and its potential to significantly improve the treatment of CNS disorders,” said Alexandre Tokay co-founder and CEO of Vect-Horus. “Our technology has been validated by the recent signature of two major licensing agreements, and offers the ability to facilitate the brain targeting of therapeutic drugs and imaging agents.”

The award winner will be announced on March 25th.

Happy new year !

Emmanuelle BETTENDORF — 2024-01-02T08:11:46Z

The Vect-Horus teams join to wish you a Happy Holiday season and Best Wishes for 2024.

Meet Vect-Horus at BIOTECH SHOWCASE, San Francisco, January 8-10, 2024

Emmanuelle BETTENDORF — 2023-12-20T10:57:25Z

From January 8 to 10, Emmanuelle Bettendorf will participate in the #BiotechShowcase at #JPM24 and will be available to meet with you on partnership opportunities.

- News / Agenda

Meet Vect-Horus at BIO International in Boston June 5-8, 2023

Elodie DORMES — 2023-06-05T13:43:00Z

Emmanuelle BETTENDORF, Sr Business Developer, will attend Bio International Convention.

- News / Agenda

Meet Vect-Horus at BIO Spring Basel, Switzerland, March 20–22, 2023

Elodie DORMES — 2023-02-17T15:13:21Z

Emmanuelle BETTENDORF will participate in BioEurope Spring from March 20 to 22, 2023 and will be available to meet with you on partnership opportunities.

- News / Agenda

Vect-Horus will be attending the BiotechShowcase 23

Elodie DORMES — 2023-01-12T15:37:22Z

From January 18 to 19, Emmanuelle Bettendorf will participate in the virtual #BiotechShowcase at #JPM23 and will be available to e-meet with you on partnership opportunities.

- News / Agenda

Vect-Horus will be attending BIO Europe from the 24th - 26th October in Germany

Elodie DORMES — 2022-10-20T15:47:00Z

This is the first in person BIOEurope since 2019 and we are excited to meet everyone face-to-face again.
Feel free to connect with Emmanuelle BETTENDORF on the platform for a meeting/coffee to discuss our DrugDelivery platform, amongt others in Neurodegenerative, Muscular, Cardiovascular and Eye diseases.

- News / Agenda